Grants
Collaborators

Attorney Officer

Chief Financial Officer

Computational Drug Discovery
Investors
AtG’s business model consists of de-risking AtG-101 and its Companion Diagnostic from a Proof of Concept Development Stage into a successful Phase I/II product and then Licensing it to a Pharmaceutical company.

AtG is currently looking for investors in order to fund the preclinical development of AtG-101.
Would it be you?